Surface Oncology (NASDAQ:SURF) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Surface Oncology (NASDAQ:SURF) from a hold rating to a sell rating in a research report sent to investors on Tuesday, Zacks.com reports.

According to Zacks, “Surface Oncology, Inc. is a clinical-stage immuno-oncology company. It develops therapies for the treatment of cancer. The company’s product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Surface Oncology is based in Cambridge, Massachusetts. “

A number of other research firms have also recently issued reports on SURF. Cowen reaffirmed a buy rating on shares of Surface Oncology in a report on Thursday, May 9th. ValuEngine raised shares of Surface Oncology from a hold rating to a buy rating in a report on Thursday, August 1st.

NASDAQ SURF opened at $1.98 on Tuesday. The company has a fifty day simple moving average of $2.45 and a two-hundred day simple moving average of $3.86. Surface Oncology has a 12-month low of $1.95 and a 12-month high of $12.65. The company has a quick ratio of 8.77, a current ratio of 8.77 and a debt-to-equity ratio of 0.24.

Institutional investors have recently modified their holdings of the stock. Paradigm Capital Management Inc. NY purchased a new position in shares of Surface Oncology during the second quarter worth $28,000. Weiss Asset Management LP purchased a new position in shares of Surface Oncology during the second quarter worth $29,000. Rhumbline Advisers purchased a new position in shares of Surface Oncology during the first quarter worth $54,000. Morgan Stanley raised its holdings in shares of Surface Oncology by 1,177.4% during the second quarter. Morgan Stanley now owns 22,751 shares of the company’s stock worth $64,000 after purchasing an additional 20,970 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Surface Oncology during the second quarter worth $82,000. 58.83% of the stock is owned by hedge funds and other institutional investors.

About Surface Oncology

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.

Further Reading: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Surface Oncology (SURF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.